Bispecific anti-egfr/anti igf-1r antibodies
AssigneeRoche Glycart AG
InventorsRalf Hosse, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Cuiying Shao, Lei Shi, Pablo Umana, Peng Wang, Katharina Wartha
Life of this patent
Estimating the term…
Abstract
The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Claims13
A bispecific antibody that binds to human EGFR and human IGF-1R comprising a first antigen-binding site that binds to human EGFR and a second antigen-binding site that binds to human IGF-1R,
- i) the first antigen-binding site comprises in the heavy chain variable domain a CDR1 of SEQ ID NO:1, a CDR2 of SEQ ID NO:2, and a CDR3 of SEQ ID NO:3, and in the light chain variable domain a CDR1 of SEQ ID NO:4, a CDR2 of SEQ ID NO:5, and a CDR3 of SEQ ID NO:6;
- and
- ii) the second antigen-binding site is a modified antigen-binding site based on the heavy chain variable domain comprising a CDR1 of SEQ ID NO:9, a CDR2 of SEQ ID NO:10, and a CDR3 of SEQ ID NO:11;
- and
- on the light chain variable domain comprising a CDR1 of SEQ ID NO:
- 12, a CDR2 of SEQ ID NO:13, and a CDR3 of SEQ ID NO:14;
- wherein the modified second antigen-binding site comprises one more modifications in one or more of the CDRs;
- and
- wherein the modified second antigen binding site has an at least 10-fold increased KD value of the binding affinity for binding to human IGF-1R compared to the unmodified second antigen binding site.
A bispecific antibody that binds to human EGFR and human IGF-1R comprising a first antigen-binding site that binds to human EGFR and a second antigen-binding site that binds to human IGF-1R, characterized in that
- i) the first antigen-binding site comprises in the heavy chain variable domain a CDR1 of SEQ ID NO:
- 1, a CDR2 of SEQ ID NO:
- 2, and a CDR3 of SEQ ID NO:3, and in the light chain variable domain a CDR1 of SEQ ID NO:
- 4, a CDR2 of SEQ ID NO:5, and a CDR3 of SEQ ID NO:6;
- and
- ii) a) the second antigen-binding site comprises in the heavy chain variable domain a CDR1 of SEQ ID NO:17, a CDR2 of SEQ ID NO:18, and a CDR3 of SEQ ID NO:19, and in the light chain variable domain a CDR1 of SEQ ID NO:20, a CDR2 of SEQ ID NO:21, and a CDR3 of SEQ ID NO:22;
- b) the second antigen-binding site comprises in the heavy chain variable domain a CDR1 of SEQ ID NO:25, a CDR2 of SEQ ID NO:26, and a CDR3 of SEQ ID NO:27, and in the light chain variable domain a CDR1 of SEQ ID NO:28, a CDR2 of SEQ ID NO:29, and a CDR3 of SEQ ID NO:30;
- c) the second antigen-binding site comprises in the heavy chain variable domain a CDR1 of SEQ ID NO:33, a CDR2 of SEQ ID NO:34, and a CDR3 of SEQ ID NO:35, and in the light chain variable domain a CDR1 of SEQ ID NO:36, a CDR2 of SEQ ID NO:37, and a CDR3 of SEQ ID NO:38;
- d) the second antigen-binding site comprises in the heavy chain variable domain a CDR1 of SEQ ID NO:41, a CDR2 of SEQ ID NO:42, and a CDR3 of SEQ ID NO:43, and in the light chain variable domain a CDR1 of SEQ ID NO:44, a CDR2 of SEQ ID NO:45, and a CDR3 of SEQ ID NO:46;
- or
- e) the second antigen-binding site comprises in the heavy chain variable domain a CDR1 of SEQ ID NO:49, a CDR2 of SEQ ID NO:50, and a CDR3 of SEQ ID NO:51, and in the light chain variable domain a CDR1 of SEQ ID NO:52, a CDR2 of SEQ ID NO:53, and a CDR3 of SEQ ID NO:54.
Dependencies are inferred from the claim text.